Canada’s drug agency recommends against public funding for new Alzheimer’s drug

Canada’s Drug Agency has decided not to cover the cost of lecanamab, a drug approved to slow early-stage Alzheimer’s disease, disappointing experts like Dr. Andrew Frank from the Bruyère Memory Program. While the drug shows promise by reducing disease progression by 27%, it comes with high costs and serious risks. Geriatrician Dr. Samir Sinha notes that the drug is not a breakthrough and highlights the need for better early diagnosis and alternative support strategies for dementia patients.

Want More Context? 🔎